Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix, Spesana Partner to Improve Workflows for Lung Cancer Molecular Diagnostic Tests

NEW YORK – Biodesix said Wednesday that it has formed a partnership with Spesana to automate the use of molecular diagnostics in clinical workflows for lung cancer. The firms expressed hope that their partnership will accelerate the adoption of precision medicine and enrollment in clinical trials.

Spesana, a startup based in Memphis, Tennessee, has developed visualization-based clinical decision support software that integrates data from electronic medical records, laboratory information systems, and molecular diagnostics to help medical practitioners make sense of MDx tests and the massive amounts of data that accompany them. The company's technology also automates referral management, tumor boards, and clinical trial management.

Through the partnership, Spesana will integrate electronic ordering of Biodesix tests, including the Nodify Lung nodule risk assessment and IQlung tests. Spesana will also provide clinical education and a virtual engagement platform.

"The Spesana platform enables easy and open communication and data sharing for all physicians within a health system to align on their patient's care," Scott Hutton, CEO of Boulder, Colorado-based Biodesix, said in a statement.

"Physicians believe in precision medicine, yet struggle with the current logistics and workflow to order, track, and receive molecular diagnostic test results to make evidence-based decisions for their patients," said Spesana CEO Carla Balch. "Together [with Biodesix], our goal is to improve the user experience with an elegant data-driven workflow and highly sensitive molecular diagnostics to improve patients' outcomes and significantly improve upon the unnecessarily complicated processes that exist now."

The Scan

For STEM Students to Stay

New policy changes will make it easier for international STEM students to stay in the US after graduation, the Wall Street Journal reports.

To Inform or Not, To Know or Not

The New York Times writes that some genetic biobanks may re-contact donors if they spot something troublesome, but it notes that not all donors want that information.

Rapid Test Studies

Researchers are examining why rapid tests may be less effective at detecting the Omicron variant and how to improve them, NPR says.

PLOS Papers on SARS-CoV-2 Diversity in Delaware, Metastatic Breast Cancer, Adiposity GWAS

In PLOS this week: genomic analysis of SARS-CoV-2 isolates from Delaware, gene expression and protein-protein interaction patterns in metastatic breast cancer, and more.